Skip to Content

Autoimmune Axonal Evaluation [A Test in Focus]

Our comprehensive panel-based approach evaluates specific antibodies which have been associated with autoimmune or paraneoplastic axonal neuropathies. Because of the overlap of clinical symptoms, we recommend a panel-based approach rather than individual antibody testing.

Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.

Testing

AIAES - Autoimmune Axonal Evaluation, Serum (Mayo ID: AIAES)

Useful for:

Identifying neuropathies with an immune mediated etiology, which are likely to respond to immunotherapies.

Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer.

Directing a focused search for cancer.

Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis.

Differentiating autoimmune axonal neuropathies from neurotoxic effects of chemotherapy.

Detecting early evidence of cancer recurrence in previously seropositive patients.

Specimen Requirements

Specimen Type: Blood

Container/Tube: Red Top

Acceptable: Serum gel

Specimen Volume: 5 mL

Performance Information

Day(s) and Time(s) Test Performed 

Monday through Friday; Varies

Analytic Time 

5 days

Samantha Rossi

Samantha Rossi

Samantha Rossi is a Marketing Associate at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.